NAD-299 ANTAGONISES 5-HT-STIMULATED AND SPIPERONE-INHIBITED [³⁵S]GTPγS BINDING IN CLONED 5-HT_1A RECEPTORS

REFERENCES

• Johansson L., Sohn D., Thorberg S.-O., Jackson D. M., Kelder D., Larsson L.-G., Rényi L., Ross S. B., Wallsten C., Eriksson H., Hu P.-S., Jerning E., Mohell N., Westlind-Danielsson A. The Pharmacological Characterization of a Novel Selective 5-Hydroxytryptamine1A Receptor Antagonist, NAD-299. J. Pharmacol. Exp. Ther. 1997; 283: 216–225
   PubMed Web of Science ®Google Scholar
• Arborelius L., Wallsten C., Ahlenius S., Svensson T. H. The Novel 5-HT1A Receptor Antagonist, NAD-299, Reverses the SSRI-Induced Inhibition of Serotonergic Cell Firing in the Dorsal Raphe Nucleus in the Rat. European Neuro-psychopharmacology 1998; 8(2)127
   PubMedGoogle Scholar
• Hjort S. In Vivo Rat Brain Microdialysis Studies of the New 5-HT1A Receptor Antagonist NAD-299. European Neuropsychopharmacology 1998; 8(2)113
   PubMedGoogle Scholar
• Hjorth S. Serotonin 5-HT1A Autoreceptor Blockade Potentiates the Ability of the 5-HT Reuptake Inhibitor Citalopram to Increase Nerve Terminal Output of 5-HT In Vivo: A Microdialysis Study. J. Neurochem. 1993; 60: 776–779
   PubMed Web of Science ®Google Scholar
• Blier P., de Montigny C. Current Advances and Trends in the Treatment of Depression. Trends Pharmacol. Sci. 1994; 15: 220–226
   PubMed Web of Science ®Google Scholar
• Artigas F., Perez V., Alvarez E. Pindolol Induces a Rapid Improvement of Depressed Patients Treated with Serotonin Reuptake Inhibitors. Arch. Gen. Psychiatry 1994; 51: 248–251
   PubMed Web of Science ®Google Scholar
• Blier P., Bergeron R. Effectiveness of Pindolol with Selected Antidepressant Drugs in the Treatment of Major Depression. J. Clin. Psychopharmacol. 1995; 15: 217–222
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A., Chaput C., Gavaudan S., Verrièle L., Millan M. J. Agonist and Antagonist Actions of (-)Pindolol at Recombinant, Human Serotonin1A (5-HT1A) Receptors. Neuropsychopharmacology 1998; 18: 395–398
   PubMed Web of Science ®Google Scholar
• Jerning E., Torell Svantesson G., Mohell N. Receptor Binding Characteristics of [3H]NAD-299, a New Selective 5-HT1A Receptor Antagonist. Eur. J. Pharmacol. 1998; 360: 219–225
   PubMed Web of Science ®Google Scholar
• Sundram H., Newman-Tancredi A., Strange P. G. Characterization of Recombinant Human Serotonin 5-HT1A Receptors Expressed in Chinese Hamster Ovary Cells. Biochem. Pharmacol. 1993; 45: 1003–1009
   PubMed Web of Science ®Google Scholar
• Markwell M.A. K., Haas S. M., Bieber L. L., Tolbert N. E. A Modification of the Lowry Procedure to Simplify Protein Determination in Membrane and Lipoprotein Samples. Anal. Biochem. 1978; 87: 206–210
   PubMed Web of Science ®Google Scholar
• Lazareno S., Farries T., Birdsall N.J. M. Pharmacological Characterization of Guanine Nucleotide Exchange Reactions in Membranes from CHO Cells Stably Transfected with Human Muscarinic Receptors m1-m4. Life Sci. 1993; 52: 449–456
   PubMed Web of Science ®Google Scholar
• Munson P. J., Rodbard D. Ligand: A Versatile Computerized Approach for Characterization of Ligand-Binding System. Anal. Biochem. 1980; 107: 220–239
   PubMed Web of Science ®Google Scholar
• Hall H., Halldin C., Sandell J., Werner T., Thorberg S. -O., Sedvall G. Autoradiographic Studies of the Labelling of 5-HT1A Receptors in the Post-Mortem Human Brain Using [11C]NAD-299 and [3H]NAD-299. European Neuropsychopharmacology 1998; 8(2)100
   Google Scholar
• Traynor J. R., Nahorski S. R. Modulation by Mu-Opioid Agonists of Guanosine-5″-O-(3-[35S]thio)Triphosphate Binding to Membranes from Human Neuroblastoma SH-SY5Y Cells. Mol. Pharmacol. 1995; 47: 848–854
   PubMed Web of Science ®Google Scholar
• Emmerson P. J., Clark M. J., Mansour A., Akil H., Woods J. H., Medzihradsky F. Characterization of Opioid Agonist Efficacy in a C6 Glioma Cell Line Expressing the Mu Opioid Receptor. J. Pharmacol. Exp. Ther. 1996; 278: 1121–1127
   PubMed Web of Science ®Google Scholar
• Lorenzen A., Guerra L., Vogt H., Schwabe U. Interaction of Full and Partial Agonists of the A1 Adenosine Receptor with Receptor/G Protein Complexes in Rat Brain Membranes. Mol. Pharmacol. 1996; 49: 915–926
   PubMed Web of Science ®Google Scholar
• Selley D. E., Sim L. J., Xiao R., Liu Q., Childers S. R. Mu-Opioid Receptor-Stimulated Guanosine-5″-O-(Gamma-Thio)-Triphosphate Binding in Rat Thalamus and Cultured Cell Lines: Signal Transduction Mechanisms Underlying Agonist Efficacy. Mol. Pharmacol. 1997; 51: 87–96
   PubMed Web of Science ®Google Scholar
• Malmberg Å., Mikaels Å., Mohell N. Agonist and Inverse Agonist Activity at the Dopamine D3 Receptor Measured by Guanosine 5″-[γ-thio]Triphosphate-[35S] Binding. J. Pharmacol. Exp. Ther. 1998; 285: 119–126
   PubMed Web of Science ®Google Scholar
• Sprouse J. S., Aghajanian G. K. Responses of Hippocampal Pyramidal Cells to Putative Serotonin 5-HT1A and 5-HT1B Agonists: A Comparative Study with Dorsal Raphe Neurons. Neuropharmacology 1988; 27: 707–715
   PubMed Web of Science ®Google Scholar
• Yocca F. D., Iben L., Meller E. Lack of Apparent Receptor Reserve at Postsynaptic 5-Hydroxytryptamine1a Receptors Negatively Coupled to Adenylyl Cyclase Activity in Rat Hippocampal Membranes. Mol. Pharmacol. 1992; 41: 1066–1072
   PubMed Web of Science ®Google Scholar
• Meller E., Goldstein M., Bohmaker K. Receptor Reserve for 5-Hydroxytryptamine1A-Mediated Inhibition of Serotonin Synthesis: Possible Relationship to Anxiolytic Properties of 5-Hydroxytryptamine1A Agonists. Mol. Pharmacol. 1990; 37: 231–237
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A., Conte C., Chaput C., Verrièle L., Millan M. J. Agonist and Inverse Agonist Efficacy at Human Recombinant Serotonin 5-HT1A Receptors as a Function of Receptors as a Function of Receptor: G-Protein Stoichiometry. Neuropharmacology 1997; 36: 451–459
   PubMed Web of Science ®Google Scholar
• Stanton J. A., Beer M. S. Characterisation of a Cloned Human 5-HT1A Receptor Cell Line Using [35S]GTP_S Binding. Eur. J. Pharmacol. 1997; 320: 267–275
   PubMed Web of Science ®Google Scholar
• De Lean A., Stadel J. M., Lefkowitz R. J. A Ternary Complex Model Explains the Agonist-Specific Binding Properties of the Adenylate Cyclase-Coupled β-Adrenergic Receptor. J. Biol. Chem. 1980; 255: 7108–7117
   PubMed Web of Science ®Google Scholar
• Kent R. S., De Lean A., Lefkowitz R. J. A Quantitative Analysis of Beta-Adrenergic Receptor Interactions: Resolution of High and Low Affinity States of the Receptor by Computer Modeling of Ligand Binding Data. Mol. Pharmacol. 1980; 17: 14–23
   PubMed Web of Science ®Google Scholar
• Malmberg Å., Mohell N., Backlund Höök B., Johansson A. M., Hacksell U., Nordvall G. Interactions of Ligands with Active and Inactive Conformations of the Dopamine D2 Receptor. Eur. J. Pharmacol. 1998; 346: 299–307
   PubMed Web of Science ®Google Scholar
• Freedman S. B., Harley E. A., Iversen L. L. Relative Affinities of Drugs Acting at Cholinoceptors in Displacing Agonist and Antagonist Radioligands: The Nms/Oxo-M Ratio as an Index of Efficacy at Cortical Muscarinic Receptors. Br. J. Pharmacol. 1988; 93: 437–445
   PubMed Web of Science ®Google Scholar
• Lahti R. A., Figur L. M., Piercey M. F., Ruppel P. L., Evans D. L. Intrinsic Activity Determinations at the Dopamine D2 Guanine Nucleotide-Binding Protein-Coupled Receptor: Utilization of Receptor State Binding Affinities. Mol. Pharmacol. 1992; 42: 432–438
   PubMed Web of Science ®Google Scholar